@article{f146a37ad22b440c88c93ace023c667b,
title = "Long-term clinical outcomes of COVID-19 patients treated with imatinib",
author = "Erik Duijvelaar and Schippers, {Job R.} and Smeele, {Patrick J.} and {de Raaf}, {Michiel Alexander} and Vanhove, {Arthur L. E. M.} and Blok, {Siebe G.} and {CounterCOVID Collaborative Group} and Twisk, {Jos W. R.} and Noordegraaf, {Anton Vonk} and {de Man}, {Frances S.} and Bogaard, {Harm Jan} and Jurjan Aman",
note = "Funding Information: JA and AVN are inventors on a patent (WO2012150857A1, 2011) covering protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase Abl-related gene (Arg). All other authors have no competing interests. ED and JRS contributed equally. Members of the CounterCOVID study group are listed in the appendix (p 12) . This project was funded with an unrestricted grant from the Amsterdam Medical Center Foundation, a bottom-up grant from NWO ZonMW (number 10430 01 201 0007), and from the Innovative Medicines Initiative 2 Joint Undertaking (number 101005142). The funding sources had no role in the design of the study, data collection, analysis, or in the decision to submit the paper for publication.",
year = "2022",
month = apr,
day = "1",
doi = "https://doi.org/10.1016/S2213-2600(22)00052-2",
language = "English",
volume = "10",
pages = "e34--e35",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "4",
}